Curative Biotechnology

Curative Biotechnology Debt

The Debt of Curative Biotechnology (CUBT) as of Oct 18, 2026 is 1.36 M USD. In the previous year, Debt was 1.37 M USD — a change of -0.80% (lower).

Debt

1.36 MUSD

YoY

-0.80%

Last updated:

In 2025, Curative Biotechnology's total debt was 1.36 M USD, a -0.80% change from the 1.37 M USD total debt recorded in the previous year.

The Curative Biotechnology Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2017
198,617.00 USD
Jan 1, 2018
198,767.00 USD
Jan 1, 2019
124.80 USD
Jan 1, 2020
559,761.00 USD
Jan 1, 2022
1.07 M USD
Jan 1, 2023
2.26 M USD
Jan 1, 2024
1.37 M USD
Jan 1, 2025
1.36 M USD
The Curative Biotechnology Debt history
YEARDebtYoY
1.36 MUSD-0.80%
1.37 MUSD-39.39%
2.26 MUSD+110.94%
1.07 MUSD+91.27%
559,761.00USD+448,426.44%
124.80USD-99.94%
198,767.00USD+0.08%
198,617.00USD+0.08%
198,467.00USD+0.27%
197,942.00USD-20.71%
249,642.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Curative Biotechnology Stock analysis

What does Curative Biotechnology do? Curative Biotechnology Inc, based in Boca Raton, Florida, provides software solutions for the healthcare market and develops therapeutic drug candidates for rare diseases. The company focuses on degenerative eye disease, infectious disease, and neuro oncology, with its primary pipeline product being a Metformin Reformulation for age-related macular degeneration. It also has ongoing programs including IMT504 for rabies and CURB906 for cancer treatment, operating with a small team of four employees since its 2001 IPO. Curative Biotechnology is one of the most popular companies on Eulerpool.

Debt Details

Understanding Curative Biotechnology's Debt Structure

Curative Biotechnology's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Curative Biotechnology's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Curative Biotechnology’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Curative Biotechnology’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Curative Biotechnology stock

Debt of Curative Biotechnology is 1.36 M USD in 2025.

Debt of Curative Biotechnology changed from 1.37 M USD to 1.36 M USD, representing a -0.80% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Curative Biotechnology since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Curative Biotechnology historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Curative Biotechnology

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Curative Biotechnology